Viridian Therapeutics, Inc.\DE (VRDN)

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Address

221 CRESCENT STREET
WALTHAM, MA 02453

Founded

2006

Number of Employees

96

Insider Transactions

Filters

Keyboard Shortcuts: Show (a) | Close (Esc)